Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-CTLA-4 / CD152 Reference Antibody (zalifrelimab) | Login | Anti-CTLA-4 / CD152 Reference Antibody (zalifrelimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-DKK1 Reference Antibody (BHQ880) | Login | Anti-DKK1 Reference Antibody (BHQ880) | ||||||||||||||||
|
||||||||||||||||||
| Anti-DLL3 Reference Antibody (Dragonfly patent anti-DLL3) | Login | Anti-DLL3 Reference Antibody (Dragonfly patent anti-DLL3) | ||||||||||||||||
|
||||||||||||||||||
| Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4) | Login | Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4) | ||||||||||||||||
|
||||||||||||||||||
| Anti-EphA2 Reference Antibody (Sanofi Aventis patent anti-EphA2) | Login | Anti-EphA2 Reference Antibody (Sanofi Aventis patent anti-EphA2) | ||||||||||||||||
|
||||||||||||||||||
| Anti-EphB4 Reference Antibody (Morphosys patent anti-EphB4) | Login | Anti-EphB4 Reference Antibody (Morphosys patent anti-EphB4) | ||||||||||||||||
|
||||||||||||||||||
| Anti-EphB4 Reference Antibody (VasGene patent anti-EphB4) | Login | Anti-EphB4 Reference Antibody (VasGene patent anti-EphB4) | ||||||||||||||||
|
||||||||||||||||||
| Anti-EPOR Reference Antibody (Abbott patent anti-EPO Receptor) | Login | Anti-EPOR Reference Antibody (Abbott patent anti-EPO Receptor) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (7A7) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (7A7) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab-MMAF) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab-MMAF) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (Duke D2C7) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Duke D2C7) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (Regeneron patent anti-EGFR) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Regeneron patent anti-EGFR) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (Shanghai Cancer Inst patent anti-EGFRvIII) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Shanghai Cancer Inst patent anti-EGFRvIII) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB2 / HER2 / CD340 Reference Antibody (BioMab patent anti-Her2) | Login | Anti-ERBB2 / HER2 / CD340 Reference Antibody (BioMab patent anti-Her2) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB2 / HER2 / CD340 Reference Antibody (coprelotamab) | Login | Anti-ERBB2 / HER2 / CD340 Reference Antibody (coprelotamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB2 / HER2 / CD340 Reference Antibody (Hersintuzumab) | Login | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Hersintuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB3/ HER3 Reference Antibody (patritumab-MMAE) | Login | Anti-ERBB3/ HER3 Reference Antibody (patritumab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERG Reference Antibody (Jackson Foundation patent anti-ERG) | Login | Anti-ERG Reference Antibody (Jackson Foundation patent anti-ERG) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FGFR1 / CD331 Reference Antibody (Lilly patent anti-FGFR-1) | Login | Anti-FGFR1 / CD331 Reference Antibody (Lilly patent anti-FGFR-1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FOLR1 / FRA Reference Antibody (Dompe patent anti-FOLR1) | Login | Anti-FOLR1 / FRA Reference Antibody (Dompe patent anti-FOLR1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) | Login | Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FGFR4 / CD334 Reference Antibody (U3-1784) | Login | Anti-FGFR4 / CD334 Reference Antibody (U3-1784) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FOLR1 / FRA Reference Antibody (mirvetuximab) | Login | Anti-FOLR1 / FRA Reference Antibody (mirvetuximab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) | Login | Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FOLR1 / FRA Reference Antibody (mirvetuximab-MMAE) | Login | Anti-FOLR1 / FRA Reference Antibody (mirvetuximab-MMAE) | ||||||||||||||||
|
||||||||||||||||||


